Rein Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Rein Therapeutics, Inc. (RNTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 32.13 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-03-26
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 0.00 shares.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 8.53K shares, a 540.54% increase year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-06-30 was 15.55K shares, a 20.76% decline year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-03-31 was 8.04K shares, a 87.49% decline year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 32.13K shares, a 62.31% decline from fiscal 2024.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 85.24K shares, a 44.76% increase from fiscal 2023.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 58.89K shares, a 272.15% increase from fiscal 2022.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 15.82K shares, a 91.69% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 8.53K shares derived: sum of 2 quarters · filed 2026-03-26 | 24.09K shares derived: sum of 3 quarters · filed 2026-03-26 | 32.13K shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 8.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 24.09K shares derived: sum of 2 quarters · filed 2025-11-14 | 32.13K shares 10-Q · filed 2025-11-14 | 32.13K shares derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | 15.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 23.60K shares 10-Q · filed 2025-08-14 | 23.60K shares derived: sum of 3 quarters · filed 2025-08-14 | 24.93K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 8.04K shares 10-Q · filed 2025-05-15 | 8.04K shares derived: sum of 2 quarters · filed 2025-05-15 | 9.38K shares derived: sum of 3 quarters · filed 2025-05-15 | 29.00K shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07 | 1.33K shares derived: sum of 2 quarters · filed 2025-04-07 | 20.96K shares derived: sum of 3 quarters · filed 2025-04-07 | 85.24K shares 10-K · filed 2025-04-07 |
| 2024-09-30 | 1.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 20.96K shares derived: sum of 2 quarters · filed 2024-11-14 | 85.24K shares 10-Q · filed 2024-11-14 | |
| 2024-06-30 | 19.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 83.91K shares 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | 64.28K shares 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | 58.89K shares 10-K · filed 2024-04-15 | |||
| 2022-12-31 | 15.82K shares 10-K · filed 2023-03-20 | |||
| 2021-12-31 | 190.39K shares 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |